Overall, dealmaking may be in a slump, but Big Pharma has been buying up biotech firms at a record pace - it's now the fastest-growing M&A sector, with deal value up 87% this year.
The typical Medicare beneficiary can expect to see about a $3 increase in their monthly premiums for prescription drug coverage in 2009, federal officials said Thursday
Western drug makers are increasingly outsourcing human clinical drug trials -- and India is getting the lion's share of the market. Is it putting millions at risk?
As Genentech's board weighs Monday's $43.7 billion merger proposal from Roche, the South San Francisco biotech has one overarching reason to fall deeper into the arms of the Swiss drug maker that already owns most of its stock: Genentech's "biological clock" is ticking.
All of 4 feet 9 inches tall, with a hook for a left hand and a résumé devoid of any time in elected office, aspiring U.S. Senator Steve Novick would be easy to write off as unelectable. That's clearly the view of the Democratic Party, which has put its weight behind his rival in the race to unseat Oregon Republican incumbent Gordon Smith in November.
Eli Lilly & Co.'s incoming chief executive believes his background in the laboratory provides the formula needed to fill the drugmaker's dwindling pipeline.
The sales rate of prescription medications slowed by more than half in 2007 to levels not seen since the early 1960s, according to a report released Wednesday.
Overall, dealmaking may be in a slump, but Big Pharma has been buying up biotech firms at a record pace - it's now the fastest-growing M&A sector, with deal value up 87% this year.
The typical Medicare beneficiary can expect to see about a $3 increase in their monthly premiums for prescription drug coverage in 2009, federal officials said Thursday
Western drug makers are increasingly outsourcing human clinical drug trials -- and India is getting the lion's share of the market. Is it putting millions at risk?
As Genentech's board weighs Monday's $43.7 billion merger proposal from Roche, the South San Francisco biotech has one overarching reason to fall deeper into the arms of the Swiss drug maker that already owns most of its stock: Genentech's "biological clock" is ticking.
All of 4 feet 9 inches tall, with a hook for a left hand and a résumé devoid of any time in elected office, aspiring U.S. Senator Steve Novick would be easy to write off as unelectable. That's clearly the view of the Democratic Party, which has put its weight behind his rival in the race to unseat Oregon Republican incumbent Gordon Smith in November.
Eli Lilly & Co.'s incoming chief executive believes his background in the laboratory provides the formula needed to fill the drugmaker's dwindling pipeline.
The sales rate of prescription medications slowed by more than half in 2007 to levels not seen since the early 1960s, according to a report released Wednesday.
Democrats have long served as the traditional enemy of Big Pharma, but in this presidential campaign, the left is taking the lion's share of drugmaker money.
Insomnia sufferers have a lot to keep them awake at night: many of the available drugs are loaded with side-effects, and big drugmakers can't seem to get their act together on new treatments.
For years, Big Pharma has kept competition from generic drug makers at bay by essentially paying its would-be rivals to stay out of its business. Now government watchdogs have declared war on these financial deals - a move that could bring cheaper drugs to market faster while costing giant drug developers billions in lost revenue.
Smaller biotechnology companies are ready to take the lead away from big pharma in developing antibiotics that can take on a new generation of deadly "superbugs."
It's looking like the number of drugs that got an OK from the Food and Drug Administration plunged in 2007, even as Big Pharma faces a slew of patent expirations.
Big Pharma, fueled by promising pipelines and cost-cutting, is poised for a strong 2008, analysts say, while projections are mixed for the biotech sector.
Eli Lilly's soon-to-be CEO John Lechleiter is an anomaly. As Lechleiter himself put it in a press conference on Tuesday: "Who would've thought that a kid who joined the company in 1979 as an organic chemist, wearing his whites, would be standing here today?"
Amgen, the nation's second-largest biotech, was once considered immune from the chronic problems facing old-line drugmakers. But these days Amgen has all the major symptoms of "Big Pharma disease:" regulatory run-ins, price competition from generic drugs, and a virtually empty pipeline of future medicines.
The page you requested cannot be found. The page you are looking for might have been removed, had its name changed, or is temporarily unavailable.
Please try the following:
• If you typed the page address in the Address bar, make sure that it is spelled correctly.
• Open the edition.cnn.com home page and look for links to the information you want.
• Use the navigation bar above to find the link you are looking for.
• Click the Back button to try another link.
• Enter a term in the search form below to look for information on CNN sites or the Internet.
Video
